| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHIC2 |
| Uniprot No | Q9UKJ5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-165aa |
| 氨基酸序列 | MADFDEIYEEEEDEERALEEQLLKYSPDPVVVRGSGHVTVFGLSNKFESEFPSSLTGKVAPEEFKASINRVNSCLKKNLPVNVRWLLCGCLCCCCTLGCSMWPVICLSKRTRRSIEKLLEWENNRLYHKLCLHWRLSKRKCETNNMMEYVILIEFLPKTPIFRPD |
| 预测分子量 | 27.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHIC2重组蛋白的3篇参考文献示例，供参考：
---
1. **文献名称**：*ETV6-CHIC2 fusion gene in acute myeloid leukemia: Functional characterization and therapeutic targeting*
**作者**：Smith J, et al.
**摘要**：本研究分析了ETV6-CHIC2融合蛋白在急性髓系白血病(AML)中的致癌机制。通过重组蛋白表达实验，发现该融合蛋白通过异常激活MAPK/ERK信号通路促进细胞增殖，并验证了靶向抑制该通路的潜在治疗策略。
2. **文献名称**：*Structural and functional analysis of the CHIC2 protein domain in transcriptional regulation*
**作者**：Lee H, et al.
**摘要**：利用重组CHIC2蛋白的晶体结构解析，揭示了其锌指结构域在DNA结合中的关键作用。实验表明，CHIC2可能通过与染色质修饰因子相互作用调控基因表达，为理解其病理学功能提供结构基础。
3. **文献名称**：*A novel CHIC2 rearrangement in pediatric leukemia: Clinical and molecular insights*
**作者**：Garcia R, et al.
**摘要**：报告一例携带新型CHIC2-ALK融合基因的儿童白血病病例。通过重组蛋白功能实验，证实该融合导致ALK激酶活性持续激活，并探讨了其对酪氨酸激酶抑制剂的敏感性。
---
**说明**：以上文献为示例，实际研究中建议通过PubMed或Web of Science检索具体文章(关键词如“CHIC2 recombinant”“ETV6-CHIC2 fusion”)。若需全文协助，可提供更具体的检索方向。
CHIC2 (Cysteine-rich hydrophobic domain 2) is a gene located on human chromosome 4q12 that encodes a protein involved in transcriptional regulation and cellular signaling. The CHIC2 protein contains conserved zinc finger domains, which enable its interaction with DNA and other proteins. It is notably associated with chromosomal translocations in hematologic malignancies, particularly through fusion with the ETV6 gene on chromosome 12. The ETV6-CHIC2 fusion gene, resulting from t(4;12)(q12;p13), generates a chimeric protein linked to the pathogenesis of chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), and other myeloproliferative disorders. This aberrant protein disrupts normal transcriptional control and promotes oncogenic signaling pathways.
Recombinant CHIC2 protein is produced using expression systems like E. coli or mammalian cells for functional studies. Purification typically involves affinity tags (e.g., His-tag) to ensure high yield and purity. Researchers utilize this protein to investigate its role in chromatin remodeling, apoptosis regulation, and interactions with signaling molecules like RAS-MAPK pathways. Its structural domains are analyzed to identify binding partners and downstream targets.
Clinically, CHIC2 serves as a biomarker for diagnosing specific leukemia subtypes. Studies on recombinant CHIC2 also aid in developing targeted therapies, such as tyrosine kinase inhibitors, by elucidating mechanisms of oncogenic fusion proteins. Despite progress, its full physiological functions and regulatory networks remain under exploration, highlighting its dual significance in basic cancer biology and translational medicine.
×
